Royalty Pharma plc (RPRX)
- Previous Close
32.90 - Open
33.08 - Bid 34.00 x 1000
- Ask 34.07 x 1200
- Day's Range
33.06 - 34.20 - 52 Week Range
24.05 - 34.20 - Volume
4,932,933 - Avg. Volume
4,612,646 - Market Cap (intraday)
19.127B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
13.89 - EPS (TTM)
2.45 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.88 (2.66%)
- Ex-Dividend Date May 16, 2025
- 1y Target Est
41.52
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
www.royaltypharma.comRecent News: RPRX
View MorePerformance Overview: RPRX
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPRX
View MoreValuation Measures
Market Cap
13.96B
Enterprise Value
19.76B
Trailing P/E
13.52
Forward P/E
11.12
PEG Ratio (5yr expected)
2.97
Price/Sales (ttm)
8.62
Price/Book (mrq)
2.09
Enterprise Value/Revenue
8.73
Enterprise Value/EBITDA
9.80
Financial Highlights
Profitability and Income Statement
Profit Margin
48.26%
Return on Assets (ttm)
7.04%
Return on Equity (ttm)
18.00%
Revenue (ttm)
2.26B
Net Income Avi to Common (ttm)
1.09B
Diluted EPS (ttm)
2.45
Balance Sheet and Cash Flow
Total Cash (mrq)
1.1B
Total Debt/Equity (mrq)
77.82%
Levered Free Cash Flow (ttm)
-1.36B